Literature DB >> 28412919

Neurological Disorders in Medical Use of Cannabis: An Update.

Renata Solimini1, Maria Concetta Rotolo1, Simona Pichini1, Roberta Pacifici1.   

Abstract

BACKGROUND &
OBJECTIVE: Medical cannabis is increasingly used as a treatment or adjunct treatment with different levels of efficacy in several neurological disorders or related symptoms (such as multiple sclerosis, autism, Parkinson and Alzheimer disease, Tourette's syndrome, Huntington's disease, neuropathic pain, epilepsy, headache), as well as in other medical conditions (e.g. nausea and vomiting, glaucoma, appetite stimulation, cancer, inflammatory conditions, asthma). Nevertheless, a number of neurological adverse effects from use of medical cannabis on the short- and on the longterm have been reported, in addition to other adverse health events.
CONCLUSION: It has been noticed that the use of medical cannabis can lead to a paradoxical effects depending on the amount of delta-9-tetrahydrocannabinol (THC) -like cannabinoids the preparation contain. Accordingly, some neurological disorders or symptoms (e.g. multiple sclerosis, seizures, epilepsy, headache) may be caused or exacerbated by the same treatment supposed to cure them. The current review presents an update of the neurological adverse effects resulting from the use of cannabis for medical purposes, highlighting the need to weigh the benefits and risks, when using cannabinoidbased treatments. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Adverse effects; Parkinson; antipsychotic; compounds; medical cannabis; neurological disorders

Mesh:

Substances:

Year:  2017        PMID: 28412919     DOI: 10.2174/1871527316666170413105421

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  10 in total

1.  Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents.

Authors:  Chloe J Jordan; Zhi-Wei Feng; Ewa Galaj; Guo-Hua Bi; Ying Xue; Ying Liang; Terence McGuire; Xiang-Qun Xie; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2020-07-24       Impact factor: 5.250

2.  Cannabis sativa CBD Extract Shows Promising Antibacterial Activity against Salmonella typhimurium and S. newington.

Authors:  Logan Gildea; Joseph Atia Ayariga; Olufemi S Ajayi; Junhuan Xu; Robert Villafane; Michelle Samuel-Foo
Journal:  Molecules       Date:  2022-04-21       Impact factor: 4.927

Review 3.  Phytocannabinoids and Cannabis-Based Products as Alternative Pharmacotherapy in Neurodegenerative Diseases: From Hypothesis to Clinical Practice.

Authors:  Yolanda Paes-Colli; Andrey F L Aguiar; Alinny Rosendo Isaac; Bruna K Ferreira; Raquel Maria P Campos; Priscila Martins Pinheiro Trindade; Ricardo Augusto de Melo Reis; Luzia S Sampaio
Journal:  Front Cell Neurosci       Date:  2022-05-30       Impact factor: 6.147

Review 4.  Prospects of Cannabidiol for Easing Status Epilepticus-Induced Epileptogenesis and Related Comorbidities.

Authors:  Dinesh Upadhya; Olagide W Castro; Raghavendra Upadhya; Ashok K Shetty
Journal:  Mol Neurobiol       Date:  2018-01-25       Impact factor: 5.590

5.  Targeting CB1 and GPR55 Endocannabinoid Receptors as a Potential Neuroprotective Approach for Parkinson's Disease.

Authors:  Eva Martínez-Pinilla; David Aguinaga; Gemma Navarro; Alberto J Rico; Julen Oyarzábal; Juan A Sánchez-Arias; José Luis Lanciego; Rafael Franco
Journal:  Mol Neurobiol       Date:  2019-01-28       Impact factor: 5.590

6.  Cedrol protects against chronic constriction injury-induced neuropathic pain through inhibiting oxidative stress and inflammation.

Authors:  Mohammad Hossein Sakhaee; Seyed Amir Hossein Sayyadi; Nader Sakhaee; Hamid R Sadeghnia; Hossein Hosseinzadeh; Fahimeh Nourbakhsh; Fatemeh Forouzanfar
Journal:  Metab Brain Dis       Date:  2020-05-29       Impact factor: 3.584

Review 7.  Endocannabinod Signal Dysregulation in Autism Spectrum Disorders: A Correlation Link between Inflammatory State and Neuro-Immune Alterations.

Authors:  Anna Lisa Brigida; Stephen Schultz; Mariana Cascone; Nicola Antonucci; Dario Siniscalco
Journal:  Int J Mol Sci       Date:  2017-07-03       Impact factor: 5.923

8.  Patient-Reported Symptom Relief Following Medical Cannabis Consumption.

Authors:  Sarah S Stith; Jacob M Vigil; Franco Brockelman; Keenan Keeling; Branden Hall
Journal:  Front Pharmacol       Date:  2018-08-28       Impact factor: 5.810

Review 9.  Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?

Authors:  Emilio Perucca
Journal:  J Epilepsy Res       Date:  2017-12-31

10.  Effects of Oral Administration of Lepidium meyenii on Morphology of Mice Testis and Motility of Epididymal Sperm Cells After Tetrahydrocannabinol Exposure.

Authors:  Adelaide Greco; Chiara Del Prete; Davide De Biase; Veronica Palumbo; Sandra Albanese; Dario Bruzzese; Domenico Carotenuto; Francesca Ciani; Simona Tafuri; Leonardo Meomartino; Marcello Mancini; Orlando Paciello; Natascia Cocchia
Journal:  Front Vet Sci       Date:  2021-12-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.